Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 8Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 8Carboplatin 6Cyclophosphamide 5veliparib 4olaparib 4Magnetic Resonance Spectroscopy 4liposomal doxorubicin 3Taxes 3Paclitaxel 3Gene Expression Profiling 3Gemcitabine 3palbociclib 2niraparib 2fludarabine 2durvalumab 2Temozolomide 2Specimen Handling 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Oxaliplatin 2Nivolumab 2Leucovorin 2Interleukin-2 2Fulvestrant 2Fluorouracil 2Early Intervention, Educational 2Drug Therapy 2Doxorubicin 2Biopsy 2130-nm albumin-bound paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × MLN 8237 × Breast × Clear all
NCT01091428 2018-06-04

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Takeda

Phase 2 Completed
191 enrolled 39 charts
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡